Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H293
UPID:
IL25_HUMAN
Alternative names:
Interleukin-17E
Alternative UPACC:
Q9H293; Q2M3F0; Q8IZV3; Q8WXB0
Background:
Interleukin-25, also known as Interleukin-17E, is a cytokine pivotal in the regulation of adaptive immune responses. Produced by eosinophils, Th2 cells, and epithelial cells, it orchestrates the cytokine production, enhancing Th2 responses. Through its receptor, IL17RA and IL17RB, it activates the JAK2-STAT5A pathway, promoting secretion of type-2 cytokines like IL4, IL9, and IL13, and induces IL8 and IL6 release via MAPK and NF-kappa-B pathways. It also plays a role in inhibiting Th17 cell differentiation.
Therapeutic significance:
Understanding the role of Interleukin-25 could open doors to potential therapeutic strategies.